Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines
This review provides an overview of electron beam (eBeam) technology and its applications across a wide variety of disciplines. More importantly, it discusses this technology’s advantages and its benefits in developing inactivated vaccines. eBeam technology is currently being used all around the wor...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/2/179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719169261502464 |
|---|---|
| author | Ruvindu Perera Suresh D. Pillai Adnan Alrubaye Palmy Jesudhasan |
| author_facet | Ruvindu Perera Suresh D. Pillai Adnan Alrubaye Palmy Jesudhasan |
| author_sort | Ruvindu Perera |
| collection | DOAJ |
| description | This review provides an overview of electron beam (eBeam) technology and its applications across a wide variety of disciplines. More importantly, it discusses this technology’s advantages and its benefits in developing inactivated vaccines. eBeam technology is currently being used all around the world for a variety of industrial applications, extending from food pasteurization to the cross-linking of polymers in the wire and cable industries. It is a successful emerging alternative for developing vaccines against bacterial, protozoan, and viral pathogens. This review includes a descriptive account of the mechanism of action of eBeam and how this technology achieves the complete inactivation of pathogens while retaining the integrity of their surface epitopes. This unique advantage is crucial for the production of efficacious vaccines. This review provides a detailed account of the usage of eBeam technology for developing vaccines to protect a multitude of hosts against a wide range of pathogens. eBeam-inactivated vaccines are advantageous over live vaccines, RNA/subunit vaccines, and chemically inactivated vaccines mainly due to the complete inactivation of pathogens, and the presence of intact, highly antigenic epitopes. To conclude, this article descriptively highlights eBeam technology’s advantages over other means of vaccine development. |
| format | Article |
| id | doaj-art-9a7a7c52cbf643b4bf2372c9d8687916 |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-9a7a7c52cbf643b4bf2372c9d86879162025-08-20T03:12:12ZengMDPI AGVaccines2076-393X2025-02-0113217910.3390/vaccines13020179Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated VaccinesRuvindu Perera0Suresh D. Pillai1Adnan Alrubaye2Palmy Jesudhasan3Cell and Molecular Biology Program, University of Arkansas, Fayetteville, AR 72701, USANational Center for Electron Beam Research, Texas A&M University, College Station, TX 77840, USACell and Molecular Biology Program, University of Arkansas, Fayetteville, AR 72701, USAPoultry Production and Product Safety Research Unit, USDA-ARS, Fayetteville, AR 72701, USAThis review provides an overview of electron beam (eBeam) technology and its applications across a wide variety of disciplines. More importantly, it discusses this technology’s advantages and its benefits in developing inactivated vaccines. eBeam technology is currently being used all around the world for a variety of industrial applications, extending from food pasteurization to the cross-linking of polymers in the wire and cable industries. It is a successful emerging alternative for developing vaccines against bacterial, protozoan, and viral pathogens. This review includes a descriptive account of the mechanism of action of eBeam and how this technology achieves the complete inactivation of pathogens while retaining the integrity of their surface epitopes. This unique advantage is crucial for the production of efficacious vaccines. This review provides a detailed account of the usage of eBeam technology for developing vaccines to protect a multitude of hosts against a wide range of pathogens. eBeam-inactivated vaccines are advantageous over live vaccines, RNA/subunit vaccines, and chemically inactivated vaccines mainly due to the complete inactivation of pathogens, and the presence of intact, highly antigenic epitopes. To conclude, this article descriptively highlights eBeam technology’s advantages over other means of vaccine development.https://www.mdpi.com/2076-393X/13/2/179electron beameBeaminactivated vaccinesbacteriavirusradiation |
| spellingShingle | Ruvindu Perera Suresh D. Pillai Adnan Alrubaye Palmy Jesudhasan Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines Vaccines electron beam eBeam inactivated vaccines bacteria virus radiation |
| title | Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines |
| title_full | Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines |
| title_fullStr | Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines |
| title_full_unstemmed | Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines |
| title_short | Leveraging Electron Beam (eBeam) Technology for Advancing the Development of Inactivated Vaccines |
| title_sort | leveraging electron beam ebeam technology for advancing the development of inactivated vaccines |
| topic | electron beam eBeam inactivated vaccines bacteria virus radiation |
| url | https://www.mdpi.com/2076-393X/13/2/179 |
| work_keys_str_mv | AT ruvinduperera leveragingelectronbeamebeamtechnologyforadvancingthedevelopmentofinactivatedvaccines AT sureshdpillai leveragingelectronbeamebeamtechnologyforadvancingthedevelopmentofinactivatedvaccines AT adnanalrubaye leveragingelectronbeamebeamtechnologyforadvancingthedevelopmentofinactivatedvaccines AT palmyjesudhasan leveragingelectronbeamebeamtechnologyforadvancingthedevelopmentofinactivatedvaccines |